CD4 and neoplasm: Hence, all the methods used so far to distinguish MF cells from reactive CD4+ cells, except possibly for single-cell DNA analysis paired with a TCR repertoire, are hampered by a selection bias, sometimes potentially collecting only some of cells from a more heterogeneous tumor population, or by mislabeling a some of the reactive cells as cancerous.